上交所(suo)下發(fa)(fa)(fa)公(gong)告(gao)，對博(bo)瑞醫藥(yao)(yao)（688166.SH）予(yu)以(yi)監管(guan)關(guan)注(zhu)，并對其時任董事會秘(mi)書王征野(ye)予(yu)以(yi)通報批(pi)評。經(jing)查明(ming)，博(bo)瑞醫藥(yao)(yao)于2月(yue)12日披露稱(cheng)，公(gong)司(si)成(cheng)功(gong)開發(fa)(fa)(fa)了瑞德(de)西韋(wei)原料藥(yao)(yao)合成(cheng)工藝和制劑技(ji)術，并已經(jing)批(pi)量(liang)(liang)生(sheng)(sheng)產(chan)(chan)出瑞德(de)西韋(wei)原料藥(yao)(yao)，瑞德(de)西韋(wei)制劑批(pi)量(liang)(liang)化生(sheng)(sheng)產(chan)(chan)正在進(jin)行中。經(jing)核實，公(gong)司(si)公(gong)告(gao)中所(suo)稱(cheng)“批(pi)量(liang)(liang)生(sheng)(sheng)產(chan)(chan)”實際為藥(yao)(yao)品研發(fa)(fa)(fa)中小(xiao)試、中試等批(pi)次的試驗性生(sheng)(sheng)產(chan)(chan)。公(gong)司(si)尚未(wei)取(qu)得(de)藥(yao)(yao)監部門批(pi)準(zhun)，也(ye)未(wei)取(qu)得(de)專利(li)權(quan)人授權(quan)，不具(ju)備(bei)進(jin)行藥(yao)(yao)物(wu)商業化批(pi)量(liang)(liang)生(sheng)(sheng)產(chan)(chan)的應有資質。